Longer than expected PFS for murlentamab when combined with FTD/TPI, particularly in patients with medium/high AMHRII expression, along with immune cascade activation in the tumor micro-environment Read more
Category Archives: News & Events
GamaMabs Pharma to present updated results at 2019 ASCO Annual Meeting from the First-In-Human clinical study of murlentamab in advanced gynecological cancers
Objective responses, good safety and evidence of stimulation of the immune system observed under murlentamab (GM102) single agent and in combination with chemotherapy Read more
GamaMabs Pharma to present new data on GM102 at two upcoming scientific conferences in November
New clinical data in Granulosa Cell Tumor (GCT) patients will be presented at the EORTC–NCI–AACR 2018 Symposium and GM102 unique T-cell activation mechanism at the AACR 2018 Conference on Tumor Immunology and Immunotherapy
GamaMabs Pharma starts a phase 2 study of monoclonal antibody GM102 in patients with advanced or metastatic colorectal cancer
C201 phase 2 will study immuno-enhancer antibody GM102, targeting AMHRII as a single agent and in combination with Trifluridine/Tipiracil (Lonsurf®)
GamaMabs Pharma to present at 2018 ASCO annual meeting results from the First-In-Human clinical study of GM102 in advanced gynecological cancers
Objective responses, good safety and evidence of stimulation of the immune system were observed with GM102 administered as a single agent in the dose-finding escalation part of the study
AACR 2018: GamaMabs Pharma to present new data on expression of Anti-Müllerian Hormone type II Receptor in non-gynecological cancers and on first ADC candidate targeting AMHRII
AMHRII expression and Antibody-Drug Conjugate preclinical data suggest potential broader applications for anti-AMHRII-based therapy
GamaMabs Pharma receives Orphan Drug Designation from US FDA for lead compound GM102
This designation has been awarded for the treatment of AMHR2-expressing ovarian cancers, exclusive of AMHR2-expressing fallopian tube cancers and primary peritoneal cancers
GamaMabs Pharma sees two peer-reviewed articles published in Oncotarget, detailing the anti-tumor activity of GM102/3C23K
First in class anti-AMHRII monoclonal antibody is currently completing early clinical phases in ovarian cancer
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells, Pauline Estupina et al., Oncotarget February 2017
Oncotarget journal published an article on GamaMabs’12G4 antibody (3C23K precursor).
Pauline Estupina, Alexandre Fontayne, Jean-Marc Barret, Nathalie Kersual, Olivier Dubreuil, Marion Le Blay, Alexandre Pichard, Marta Jarlier, Martine Pugnière, Maëva Chauvin, Thierry Chardès, Jean-Pierre Pouget, Emmanuel Deshayes, Alexis Rossignol, Toufik Abache, Christophe de Romeuf, Aurélie Terrier, Lucie Verhaeghe, Christine Gaucher, Jean-François Prost, André Pèlegrin, Isabelle Navarro-Teulon, (2017) The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells, Oncotarget
GamaMabs Pharma strengthens its governance with the appointment of Martine J George, M.D., as independent board member
